Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 300.00
Bid: 298.50
Ask: 301.50
Change: 13.00 (4.53%)
Spread: 3.00 (1.005%)
Open: 280.50
High: 304.50
Low: 280.50
Prev. Close: 287.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holdings in Company

1 Jul 2020 18:30

RNS Number : 7785R
Oxford Biomedica PLC
01 July 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Oxford Biomedica plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii: CHANGE IN NATURE : RETURN OF LOANED SHARES

X

3. Details of person subject to the notification obligationiv

Name

Aviva plc & its subsidiaries

City and country of registered office (if applicable)

London, England

4. Full name of shareholder(s) (if different from 3.)v

Name

Registered Holder:

Chase (GA Group) Nominees Limited 1,850,231*

 

HSBC Global Custody Nominee (UK) Limited 709,781*

State Street Nominees Limited 11,522*

*denotes direct interest

 

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

30/06/2020

6. Date on which issuer notified (DD/MM/YYYY):

01/07/2020

 

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

3.13%

 

0.00%

3.13%

 

82,002,369

Position of previous notification (if

applicable)

2.87%

0.26%

3.13%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary SharesGB00BDFBVT43

2,571,534

Not Disclosable

3.13%

Not Disclosable

SUBTOTAL 8. A

2,571,534

3.13%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Aviva plc

3.13%

Aviva Group Holdings Limited

3.13%

Aviva Investors Holdings Limited

3.13%

Aviva Investors Global Services Limited

3.13%

 

 

 

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

See Section 4

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

This notification is prompted by a

 

Place of completion

Norwich, England

Date of completion

01 July 2020

 

Contact name:

Natalie Walter

Contact telephone number:

01865 783000

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLEAXXFEAPEEFA
Date   Source Headline
25th Jul 20177:00 amRNSNotice of Interim Results
24th Jul 201710:10 amRNSDirector Dealings / Market Share Purchase
18th Jul 20178:47 amRNSDirector Dealings / Market Share Sale and Purchase
14th Jul 20174:49 pmRNSDirector/PDMR Shareholding
14th Jul 20173:30 pmRNSPDMR Shareholding
14th Jul 201711:41 amRNSLTIP for Long Term Incentive Plan
13th Jul 201712:38 pmRNSDirector Dealings / Market Share Sale and Purchase
13th Jul 20177:15 amRNSHoldings in Company
13th Jul 20177:00 amRNSFDA AdCom Recommends CTL019 for Approval
11th Jul 20179:29 amRNSDirector Dealings / Market Share Sale and Purchase
7th Jul 201710:15 amRNSHardman Research: Major deal to supply Novartis
6th Jul 20177:15 amRNSHolding(s) in Company
6th Jul 20177:00 amRNSMajor Commercial and Clinical Supply Agreement
3rd Jul 20172:20 pmRNSTotal Voting Rights
3rd Jul 20172:18 pmRNSBlock Listing
30th Jun 201710:38 amRNSRefinancing of Debt Facility
23rd Jun 201710:12 amRNSDirector Dealings / Market Share Purchase
14th Jun 20173:00 pmRNSFindings from Phase II JULIET Study
7th Jun 20177:00 amRNSOXB notes FDA Advisory Committee to review CTL019
2nd Jun 20177:00 amRNSOXB to Present at Jefferies Healthcare Conference
1st Jun 201712:22 pmRNSTotal Voting Rights
24th May 20171:55 pmRNSDirector/PDMR Shareholding
23rd May 20172:03 pmRNSResult of AGM
4th May 20178:46 amRNSTotal Voting Rights
28th Apr 20177:00 amRNSAnnual Report and Accounts & AGM Notification
24th Apr 201710:17 amRNSDirector/PDMR Shareholding
4th Apr 20177:00 amRNSHolding(s) in Company
3rd Apr 20179:11 amRNSTotal Voting Rights
31st Mar 20177:15 amRNSHardman: Delivering commercial gene-therapy vector
30th Mar 20177:02 amRNSBLA filing for CTL019
27th Mar 201710:44 amRNSPublication in the Journal Nature Communications
23rd Mar 20171:47 pmRNSDirector Dealings
22nd Mar 20177:00 amRNSHolding(s) in Company
16th Mar 20177:00 amRNSPRELIMINARY RESULTS FOR THE YEAR ENDED 31 DEC 2016
10th Mar 20177:00 amRNSNotice of Preliminary Results
1st Mar 201710:24 amRNSTotal Voting Rights
28th Feb 20177:00 amRNSAppointment of New Chief Financial Officer
24th Feb 20179:36 amRNSDirector Dealings
24th Feb 20177:00 amRNSResults of TroVax® in Advanced Colorectal Cancer
1st Feb 201710:09 amRNSTotal Voting Rights
25th Jan 20179:02 amRNSDirector/PDMR Shareholding
24th Jan 20174:34 pmRNSDirector Dealings / Market Share Purchase
24th Jan 20179:31 amRNSDirector/PDMR Shareholding
23rd Jan 20179:57 amRNSDirector/PDMR Shareholding
3rd Jan 20179:30 amRNSBlock Listing Return
3rd Jan 20179:28 amRNSTotal Voting Rights
20th Dec 20168:57 amRNSDirector/PDMR Shareholding
12th Dec 201610:52 amRNSBlock listing application
6th Dec 20169:15 amRNSDirector/PDMR Shareholding
5th Dec 201610:25 amRNSFindings Reported by Novartis on CTL-019 at ASH

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.